Show simple item record

dc.contributor.authorKELLEHER, DERMOT P
dc.contributor.authorWEIR, DONALD
dc.date.accessioned2009-10-07T18:50:01Z
dc.date.available2009-10-07T18:50:01Z
dc.date.issued2002
dc.date.submitted2002en
dc.identifier.citationN. Mahmud, D. O'Toole, N. O'Hare, P. J. Freyne, D. G. Weir and D. Kelleher `Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis? in Alimentary Pharmacology and Therapeutics, 16, (2), 2002,pp 207-215en
dc.identifier.otherYen
dc.identifier.otherY
dc.identifier.other21303
dc.identifier.urihttp://hdl.handle.net/2262/33838
dc.descriptionPUBLISHEDen
dc.description.abstractBACKGROUND: A number of cases of nephrotoxicity have been reported in patients with inflammatory bowel disease taking oral 5-aminosalicylic acid (5-ASA). AIM: To evaluate the effects of 9 months of therapy with mesalazine or olsalazine on renal function in patients with ulcerative colitis in remission. METHODS: Forty patients with ulcerative colitis in complete remission for 6 months were randomized to either olsalazine (n=20) or mesalazine (n=20 for nine months). Thirty-six of the 40 patients were on prior salicylate therapy. Disease activity was the measure ofclinical efficacy and was assessed by the Harvey-Bradshaw Index (HBI). Laboratory efficacy measurements included glomerular filtration rate (GFR), microalbuminuria, urinary gluthathione S-transferase (GST) and serum C-reactive protein (CRP). Safety analysis consisted of documentation of adverse events and laboratory values. RESULTS: There was no significant reduction in the GFR overall on therapy. The levels of GFR adjusted for baseline were similar in the two treatment groups after 3, 6 and 9 months. A significantly higher percentage of mesalazine-treated patients experienced drug related adverse events, all of a minor nature. The incidence of adverse events causing early withdrawal was similar in the two treatment groups. CONCLUSION: Treatment with mesalazine or olsalazine for 9 months had no significant impact on GFR.en
dc.description.sponsorshipThis study was supported by Kabi Pharmacia (now Pharmacia Upjohn).en
dc.format.extent207-215en
dc.format.extent239763 bytes
dc.format.mimetypeapplication/pdf
dc.language.isoenen
dc.publisherJohn Wileyen
dc.relation.ispartofseriesAlimentary Pharmacology and Therapeuticsen
dc.relation.ispartofseries16en
dc.relation.ispartofseries2en
dc.rightsNen
dc.subjectClinical Medicineen
dc.titleEvaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitisen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/kellehdp
dc.identifier.rssinternalid21303
dc.identifier.rssurihttp://dx.doi.org/10.1046/j.1365-2036.2002.01155.x


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record